EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

7. Which DSCSA and provenance responsibilities apply to this arrangement?

Dose Diligence research deskSection 06 · Page 10 of 22Last updated 17 Nov 2026

Framing: assign obligations by activity and product before buying traceability software. FDA’s current small-dispenser exemption is limited to specified requirements. Its eligibility definition concerns the owning company’s pharmacist and qualified pharmacy-technician employees; the letter preserves other obligations. A clinic’s prescriber count is therefore not the relevant eligibility test. (fda.gov)

Put to: Jesse Dresser and Michael Ganio.
Buyer owner: Compliance lead and procurement.

Why it matters: The buyer needs to know what it must do itself, what its trading partners must do and what records must remain accessible during a recall or suspect-product investigation.

A good answer should cover:

  • Whether the clinic’s actual activities make it a relevant trading partner or dispenser.
  • The applicable obligations for the product and transaction, including any exclusions or exemptions.
  • Supplier authorisation checks, required transaction records and suspect-product escalation.
  • How records remain usable if a software vendor, wholesaler or pharmacy relationship ends.
  • The precise basis and dates for any claimed exemption.

Follow-up that tests the answer: “Produce the records and escalation chain for one selected package or lot without relying on the account manager.”

Evidence to request: A counsel-approved responsibility matrix and traceability drill. Keep provenance controls for compounded preparations distinct from an unsupported assumption that every product follows the same DSCSA pathway.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
Section sources →